

Optimizing Dose Intensity of Treatment for Patients With Metastatic Renal Cell Carcinoma

Project Leader:

Roberto Pili, MD

Chief of the Genitourinary Section
Roswell Park Cancer Institute
Buffalo, New York

Developed through an independent educational grant from *Pfizer, Inc.*

Goal:

- To improve clinician knowledge and self-reported performance of clinical care for patients with Metastatic Renal Cell Carcinoma (mRCC); namely, choosing therapy, optimizing dose, and managing adverse effects.

Method: *MeDscape* CME Presentation

Case-based, roundtable discussion between

- **Dr. Roberto Pili**, former Professor of Oncology at Roswell Park Cancer Institute, and
- **Dr. Michael Krabak**, Community Oncologist.



Learning Objectives

Upon completion of this activity, participants will be able to:

- 1. **Identify standard treatment for mRCC with regard to dosing schedule; adverse effect profiles; dosing flexibility, and dose intensity;**
- 2. **Identify common adverse effects associated with agents used to treat mRCC, and strategies for managing toxicities;**
- 3. **Describe the effect of dose reductions and interruptions on clinical outcomes;**
- 4. **Identify customized dosing strategies to maximize drug exposure for patients being treated with targeted therapies for mRCC;**
- 5. **Develop a comprehensive care plan to monitor and manage patients with mRCC.**



Results

- **1,273 people viewed this event**, 813 physicians and 469 “other” Health Care Professionals
- **Correct knowledge test responses** when compared pre and post event were significantly–improved (P<.05)
- **91% of those participating** reported they would recommend it to others; **96%** believed participating in this activity promoted better health care.
- **Participants expressed** a desire for more CME programing in oncology, and the use of case-based information.

